Previous Pause Next
Home >> News Center >>
Clinical Trials
Cempra Pharmaceuticals, Inc. Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) PDF Print E-mail
Saturday, 17 September 2011 01:31

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago.

Read more...
 
Inovio Pharmaceuticals (INO) Completes PENNVAX(TM)-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses PDF Print E-mail
Saturday, 17 September 2011 01:27

Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

Read more...
 
DMC Is First In Detroit Area To Begin Patient Enrollment For Obstructive Sleep Apnea Clinical Trial PDF Print E-mail
Friday, 16 September 2011 16:45
Detroit Medical Center (DMC) has been selected as the first Detroit area hospital to participate in a pivotal clinical study to evaluate the safety and effectiveness of a new therapy for patients with moderate to severe obstructive sleep apnea (OSA).
Read more...
 
Phase IIIb Study Shows Benefits of Combining Onglyza with Insulin for Type 2 Diabetes PDF Print E-mail
Friday, 16 September 2011 16:39

Partners Bristol-Myers Squibb and AstraZeneca reported positive data from a Phase IIIb study evaluating the addition of the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza™ (saxagliptin) to ongoing insulin therapy (with or without metformin) in adult patients with type II diabetes.

Read more...
 
Viamet Pharmaceuticals Initiates Phase 1 Clinical Program with Novel Antifungal Agent VT-1161 PDF Print E-mail
Thursday, 15 September 2011 00:26

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent.

Read more...
 
Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting PDF Print E-mail
Thursday, 15 September 2011 00:23

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company’s study of eculizumab (Soliris®) in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

Read more...
 
ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product FibrocapsTM and Targets Start of Phase III in H1 2012 PDF Print E-mail
Wednesday, 14 September 2011 01:35

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead product Fibrocaps in surgical hemostasis.

Read more...
 
Acceleron Initiates Phase 1 Study of ACE-536 PDF Print E-mail
Wednesday, 14 September 2011 01:25

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.

Read more...
 
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) PDF Print E-mail
Wednesday, 14 September 2011 01:12
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today  that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze™ technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE).
Read more...
 
HemaQuest Pharmaceuticals Completes Patient Enrollment In Phase 2 Clinical Study Of HQK-1001 In Patients With Sickle Cell Disease PDF Print E-mail
Tuesday, 13 September 2011 00:55
HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
Read more...
 
BioLineRx Ltd. Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain PDF Print E-mail
Saturday, 17 September 2011 01:29
BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced today the last visit of the last subject and preliminary results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.
Read more...
 
Phenex Pharmaceuticals AG Begins Phase I First-In-Man Study With its Clinical Development Candidate Px-102 PDF Print E-mail
Saturday, 17 September 2011 01:25
Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist.
Read more...
 
Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD PDF Print E-mail
Friday, 16 September 2011 16:43
Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced that an independent Data Safety Monitoring Board (DSMB) recently completed a pre-specified interim analysis for safety and futility for Soligenix's confirmatory Phase 3 clinical trial of orBec® an oral formulation of beclomethasone dipropionate (BDP) in acute gastrointestinal Graft-versus-Host disease (GI GVHD).
Read more...
 
ChemoCentryx Reports CCX140-B Meets Primary Endpoint And Demonstrates Clinical Efficacy In Phase II Study In Type 2 Diabetes PDF Print E-mail
Friday, 16 September 2011 16:38
ChemoCentryx, Inc. today announced that the Company's novel, orally active CCR2 antagonist, CCX140-B, demonstrated an excellent safety profile and exhibited clear signs of biological and clinical effect in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
Read more...
 
ConjuChem Initiates Phase 2 Study of Diabetes Drug PDF Print E-mail
Thursday, 15 September 2011 00:25

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

Read more...
 
Aeterna Zentaris Presents Positive Final Phase 2 Efficacy And Safety Data For AEZS-108 In Advanced Endometrial Cancer At ESGO Meeting In Milan, Italy PDF Print E-mail
Thursday, 15 September 2011 00:22
Aeterna Zentaris Inc. (the "Company") earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.
Read more...
 
BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP® biotherapy for metastatic melanoma PDF Print E-mail
Wednesday, 14 September 2011 01:33

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis.

Read more...
 
Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids PDF Print E-mail
Wednesday, 14 September 2011 01:25
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids.
Read more...
 
Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer PDF Print E-mail
Tuesday, 13 September 2011 00:58

Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC).

Read more...
 
Oncothyreon Initiates Phase 2 Trial Of Its PI-3 Kinase Inhibitor PX-866 In Patients With Prostate Cancer PDF Print E-mail
Tuesday, 13 September 2011 00:55
Oncothyreon Inc. (Nasdaq: ONTY) announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 122